Al MJ, Maniadakis N, Grijseels EWM, Janssen M. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands. Value Health 2008; 11: 589-599.
Attema AE. De rol van tijdsvoorkeur bij de waardering van gezondheid. TPEdigitaal 2008; 2: 92-105.
Attema AE, Brouwer WBF. Can we fix it? Yes we can! But what? A new test of procedural invariance in TTO-measurement. Health Econ 2008; 17: 877-885.
Van Baal PHM, Brouwer WBF, De Wit GA, Hoogenveen RT, Polder JJ. De invloed van roken en overgewicht op zorguitgaven. Tijdschrift voor gezondheidswetenschappen 2008; 86: 150-155.
Van Baal PHM, Polder JJ, De Wit GA, Hoogenveen RT, Feenstra TL, Boshuizen HC, Engelfriet PM, Brouwer WBF. Lifetime medical costs of obesity: prevention no cure for increasing health expenditure. PLoS Med 2008; 5: e29.
Van den Berg B, Al MJ, Van Exel NJA, Koopmanschap MA, Brouwer WBF. Economic valuation of informal care: conjoint analysis applied in a heterogeneous population of informal caregivers. Value Health 2008; 11: 1041-1050.
Van den Bos T, Visser-Meily A, Van Exel NJA. De praktijkondersteuner meer in beeld in de zorg aan CVA-patiënten. Tijdschrift voor Praktijkondersteuning 2008; 3: 7-10.
Bouwmans CAM, Lintsen BAME, Al MJ, Verhaak CM, Eijkemans RJC, Habbema JDF, Braat DDM, Hakkaart-van Roijen L. Absence from work and emotional stress in women undergoing IVF or ICSI: an analysis of IVF-related absence from work in women and the contribution of general and emotional factors. Acta Obstet Gynecol Scand 2008; 87: 1169-1175.
Bouwmans CAM, Lintsen BME, Eijkemans MJC, Habbema JDF, Braat DDM, Hakkaart L. A detailed cost analysis of in vitro fertilization and intracytoplasmic sperm injection treatment. Fertil Steril 2008; 89: 331-341.
Breekveldt-Postma NS, Koerselman J, Erkens JA, Van der Molen T, Lammers JWJ, Herings RMC. Treatment with inhaled corticosteroids in asthma is too often discontinued. Pharmacoepidemiol Drug Saf 2008; 17: 411-422.
Brouwer WBF. Perspective, costs, outcomes and discounting in pharmacoeconomic evaluations. Eur J Hosp Pharm Pract 2008; 14: 20-22.
Brouwer WBF, Culyer AJ, Van Exel NJA, Rutten FFH. Welfarism vs. extra-welfarism. J Health Econ 2008; 27: 325-338.
Brouwer WBF, Van Exel NJA, Van Baal PHM. Kosten in gewonnen levensjaren niet langer negeren! TSG 2008; 86: 1-2.
Brouwer WBF, Van Exel NJA, Baker R, Donaldson C. The new myth: the social value of the QALY.Pharmacoeconomics 2008; 26: 1-4.
Brouwer WBF, Rutten FFH. Een kwaliteitsinstituut voor de zorg: liever vandaag dan morgen! VGE Infobulletin 2008; 25: 4-6.
Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Mölken MPMH, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-469.
Cohen JP, Stolk EA, Niezen MGH. Role of budget impact in drug reimbursement decisions. J Health Polit Policy Law 2008; 33: 225-247.
Delhaas EM, Beersen N, Redekop WK, Klazinga NS. Long-term outcomes of continuous intrathecal baclofen infusion for treatment of spasticity: a prospective multicenter follow-up study. Neuromodulation 2008; 11: 227-236.
Van Exel NJA, Bobinac A, Koopmanschap MA, Brouwer WBF. The invisible hands made visible: recognizing the value of informal care in healthcare decision-making. Expert Review of Pharmacoeconomics & Outcomes Research 2008; 8: 557-561.
Van Exel NJA, De Graaf G, Brouwer WBF. Give me a break! Informal caregiver attitudes towards respite care.Health Policy 2008; 88: 73-87.
Van Exel NJA, De Ruiter M, Brouwer WBF. When time is not on your side: patient experiences with waiting for home care and admission to a nursing or residential home. The Patient 2008; 1: 55-71.
Feenstra TL, Van Baal PHM, Gandjour A, Brouwer WBF. Future costs in economic evaluation: a comment on Lee. J Health Econ 2008; 27: 1645-1649.
Galani C, Al MJ, Schneider H, Rutten FFH. Uncertainty in decision-making: value of additional information in the cost-effectiveness of lifestyle intervention in overweight and obese people. Value Health 2008; 11: 424-434.
Galani C, Rutten FFH. Self-reported healthcare decision-makers’ attitudes towards economic evaluations of medical technologies. Curr Med Res Opin 2008; 24: 3049-3058.
Gischler SJ, Mazer P, Poley MJ, Tibboel D, Van Dijk M. Telephone helpline for parents of children with congenital anomalies. J Adv Nurs 2008; 64: 625-631.
Goossens LMA, Standaert B, Hartwig N, Hövels AM, Al MJ. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008; 26: 1118-1127.
Groenewoud AS, Van Exel NJA, Berg M, Huijsman R. Building quality report cards for geriatric care in The Netherlands: using concept mapping to identify the appropriate “building blocks” from the consumer’s perspective. Gerontologist 2008; 48: 79-92.
Heijink R, Noethen M, Renaud T, Koopmanschap MA, Polder J. Cost of illness: an international comparison Australia, Canada, France, Germany and The Netherlands. Health Policy 2008; 88: 49-61.
Hoogendoorn M, Welsing P, Rutten-van Mölken MPMH. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008; 24: 51-61.
Kerremans JJ, Verboom P, Stijnen T, Hakkaart-van Roijen L, Goessens W, Verbrugh HA, Vos MC. Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use. J Antimicrob Chemother 2008; 61: 428-435.
Koopmanschap MA, Van Exel NJA, Van den Berg B, Brouwer WBF. An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics 2008; 26: 269-280.
Koopmanschap MA, Van Exel NJA, Van den Berg B, Brouwer WBF. Una panoramica delle metodologie per la valutazione delle cure informali negli studi di economia sanitaria. Pharmacoeconomics Italian Research Articles 2008; 10: 99-111.
Kreuger L, Van Exel NJA, Nieboer A. Needs of persons with severe intellectual disabilities: a Q-methodological study of clients with severe behavioural disorders and severe intellectual disabilities. Journal of Applied Research in Intellectual Disabilities 2008; 21: 466-476.
Kuijsten R, Cramm JM, Van Exel NJA, Finkenflügel H. Werkt werken? Een Q-methodologisch onderzoek naar de mening van mensen met een verstandelijke beperking over de bijdrage van individueel begeleid werken aan hun sociale integratie. Nederlands Tijdschrift voor de Zorg aan mensen met verstandelijke beperkingen (NTZ) 2008; 34: 34-46.
Lamers LM, Stupp R, Van den Bent MJ, Al MJ, Gorlia T, Wasserfallen JB, Mittmann N, Jin Seung S, Crott R, Uyl-de Groot CA. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer 2008; 112: 1337-1344.
Nijdam WM, Levendag PC, Noever I, Schmitz PI, Uyl-de Groot CA. Longitudinal changes in quality of life and costs in long-term survivors of tumors of the oropharynx treated with brachytherapy or surgery.Brachytherapy 2008; 7: 343-350.
Oostenbrink JB, Al MJ, Oppe M, Rutten-van Mölken MPMH. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. Value Health 2008; 11: 1070-1080.
Polder JJ, Brouwer WBF. Rechtvaardige verdeling: het verhaal van Bart, Johan, Werner en Kees. Tien woorden gezondheidseconomie (4). TSG 2008; 86: 63-68.
Poley MJ, Brouwer WBF, Busschbach JJV, Hazebroek FWJ, Tibboel D, Rutten FFH, Molenaar JC. Cost-effectiveness of neonatal surgery: first greeted with scepticism, now increasingly accepted. Pediatr Surg Int 2008; 24: 119-127.
Rappange DR, Van Baal PH, Van Exel NJA, Feenstra TL, Rutten FFH, Brouwer WBF. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?Pharmacoeconomics 2008; 26: 815-830.
Redekop WK, Orlewska E, Maciejewski P, Rutten FFH, Niessen LW. Costs and effects of secondary prevention with perindopril in stable coronary heart disease in Poland: an analysis of the EUROPA study including 1251 Polish patients. Pharmacoeconomics 2008; 26: 861-877.
Rutten FFH, Vulto AG. Pharmacoeconomics: science, practice and challenges. Eur J Hosp Pharm Pract 2008; 14: 16.
Scalone L, Mantovani LG, Krol M, Rofail D, Ravera S, Bisconte MG, Borgna-Pignatti C, Borsellino Z, Cianciulli P, Gallisai D, Prossomariti L, Stefàno I, Cappellini MD. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study.Curr Med Res Opin 2008; 24: 1905-1917.
Steenhoek A, Uyl-de Groot CA, Rutten FFH. Uitkomstenonderzoek: hoogste tijd voor een definitie! TSG 2008; 86: 18-21.
Tan SS, Hakkaart-van Roijen L, Al MJ, Bouwmans CAM, Hoogendoorn ME, Spronk PE, Bakker J. A microcosting study of intensive care unit stay in the Netherlands. J Intensive Care Med 2008; 23: 250-257.
Tan SS, Redekop WK, Rutten FFH. Costs and prices of single dental fillings in Europe: a micro-costing study.Health Econ 2008; 17: S83-S93.
Tielen M, Van Staa AL, Jedeloo S, Van Exel NJA, Weimar W. Q-methodology to identify young adult renal transplant recipients at risk for nonadherence. Transplantation 2008; 85: 700-706.
Utens CMA, Goossens LMA, Smeenk FWJM, van Schayck OCP, van Litsenburg W, Janssen A, van Vliet M, Seezink W, Demunck DRAJ, van de Pas B, de Bruijn PJ, van der Pouw A, Retera JMAM, de Laat-Bierings P, van Eijsden L, Braken M, Eijsermans R, Rutten-van Molken MPMH. Effectiveness and cost-effectiveness of early assisted discharge for Chronic Obstructive Pulmonary Disease exacerbations: the design of a randomised controlled trial. BMC Public Health 2010, 10:618
Van Wetering CR, Van Nooten FE, Mol SJM, Hoogendoorn M, Rutten-van Mölken MPMH, Schols AM. Systemic impairment in relation to disease burden in patients with moderate COPD eligible for a lifestyle program: findings from the INTERCOM trial. Int J Chron Obstruct Pulmon Dis 2008; 3: 443-451.